ESC Congress 2025 - EMORI-HCM finds that right ventricular pacing (iRVP) improves symptoms in obstructive hypertrophic cardiomyopathy (oHCM) patients.

Dr Ahran Arnold (Imperial College London, UK) discusses findings from the EMORI-HCM study, exploring electro-mechanically optimised right ventricular pacing as a novel therapeutic approach for patients with oHCM.

This interventional trial examined the potential of optimised pacing strategies in managing the symptoms of oHCM. The study recruited 60 patients with who either had existing implantable cardioverter defibrillators (ICDs) or were scheduled for ICD/pacemaker implantation. Using high-precision haemodynamic and echocardiographic techniques, researchers assessed how adjusting pacing lead positioning and atrioventricular delay optimisation could reduce left ventricular outflow tract (LVOT) gradients and improve blood pressure parameters.

The EMORI-HCM trial found this pacing strategy, which uses electromechanically optimized right ventricular pacing, significantly improved symptoms and exercise capacity in a select group of patients with oHCM.

Interview Questions:
1. What is the current treatment landscape for oHCM?
2. What was the study design and patient population?
3. What were the key findings?
4. How do these results translate into clinical practice?
5. What are your take-home messages?
6. What further research is needed in this area?

Recorded on-site at ESC Congress 2025, Madrid.
Editors: Jordan Rance, Yazmin Sadik
Videographer: Dan Brent, Mike Knight, Oliver Miles, David Ben-Harosh
Support: This is an independent interview produced by Radcliffe Cardiology.